Following the discontinuation of the development of cobitolimod and the announcement that the Company will not continue the development of any of its other compounds, various options for the Company's future have, as previously communicated, been evaluated in order to maximize shareholder value. The evaluation, which was conducted with support from an external financial advisor, resulted in continuation of the reversed merger and in taking further steps to ensure that such a transaction is achievable.
In order to implement the planned reverse merger as soon as practically possible, the Board of Directors of
As stated in the notice, the Board of Directors proposes that the Extraordinary General Meeting resolves to adopt new Articles of Association including mainly the following amendments: (i) new company name and objects of the company, (ii) new limits for the share capital and number of shares, (iii) introduction of a new class of redeemable shares of series C and (iv) introduction of a conversion clause whereby holders of ordinary shares may request conversion into shares of series C. The Articles of Association in its complete proposed new wording will be available on the Company's website no later than two weeks prior to the Extraordinary General Meeting.
Provided that the Company enters into an agreement on the intended Transaction, the Board of Directors of
For more information, see the notice of the Extraordinary General Meeting, which is published through a separate press release.
For more information:
Phone: +46 8 122 038 50
E-mail: jenny.sundqvist@indexpharma.com
Johan Giléus, CFO and deputy CEO
Tel: +46 8 122 038 50
E-mail: johan.gileus@indexpharma.com
Publication
The information was submitted for publication through the agency of the contact person set out above at
This is an English translation of the Swedish press release. In case of discrepancies between the English translation and the Swedish press release, the Swedish press release shall prevail. Information in this press release is intended for investors.
https://news.cision.com/index-pharmaceuticals/r/index-pharmaceuticals-provides-a-status-update-and-informs-about-extraordinary-general-meeting-on-ju,c3974391
https://mb.cision.com/Main/9612/3974391/2781573.pdf
(c) 2024 Cision. All rights reserved., source